Be Careful Using Gliptins in Heart Failure Patients

See updated information from the FDA concerning heart failure risk with saxagliptin and alogliptin

You'll see new warnings about a possible increased risk of heart failure with saxagliptin (Onglyza, etc) and alogliptin (Nesina, etc).

So far, saxagliptin has the strongest evidence. There's one heart failure hospitalization for every 143 patients treated with saxagliptin over 2 years.

Alogliptin seems less likely to be linked to heart failure...sitagliptin (Januvia) doesn't seem to be a problem...and it's too early to say if linagliptin (Tradjenta) increases risk.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote